Therapeutically interchangeable? A study of real‐world outcomes associated with switching basal insulin analogues among US patients with type 2 diabetes mellitus using electronic medical records data-Reference-Cited by-同舟云学术

Therapeutically interchangeable? A study of real‐world outcomes associated with switching basal insulin analogues among US patients with type 2 diabetes mellitus using electronic medical records data

Published:2014-12-04 Issue:3 Volume:17 Page:245-253
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Levin P.¹,Wei W.²,Miao R.²,Ye F.²,Xie L.³,Baser O.³⁴⁵,Gill J.²

Affiliation:

1. Model Clinical Research Baltimore MD USA

2. Sanofi US, Inc. Bridgewater NJ USA

3. STATinMED Research Ann Arbor MI USA

4. Department of Internal Medicine University of Michigan Ann Arbor MI USA

5. School of Economy MEF University Istanbul Turkey

Funder

Sanofi

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.12407

Reference24 articles.

1. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

2. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes

3. Insulin detemir versus insulin glargine for type 2 diabetes mellitus;Swinnen SG;Cochrane Database Syst Rev,2011

4. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes

5. Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluating the Representativeness of US Centricity Electronic Medical Records With Reports From the Centers for Disease Control and Prevention: Comparative Study on Office Visits and Cardiometabolic Conditions;JMIR Medical Informatics;2020-06-03

2. Insulin insulated: barriers to competition and affordability in the United States insulin market;Journal of Law and the Biosciences;2020-01

3. Hypoglycaemia and treatment patterns among insulin‐treated patients with type 2 diabetes who switched to insulin glargine 300 units/mL versus other basal insulin in a real‐world setting;Endocrinology, Diabetes & Metabolism;2019-06-14

4. Continuation with apixaban treatment is associated with lower risk for hospitalization and medical costs among elderly patients;Current Medical Research and Opinion;2019-06-05

5. Diabetes management and treatment approaches outside of North America and West Europe in 2006 and 2015;Acta Diabetologica;2019-04-08